Filing Details
- Accession Number:
- 0001179110-20-001370
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-10 16:34:06
- Reporting Period:
- 2020-02-06
- Accepted Time:
- 2020-02-10 16:34:06
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1650664 | Editas Medicine Inc. | EDIT | Biological Products, (No Disgnostic Substances) (2836) | 464097528 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1682323 | Charles Albright | C/O Editas Medicine, Inc. 11 Hurley St. Cambridge MA 02141 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-02-06 | 11,593 | $0.00 | 32,146 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2020-02-07 | 622 | $26.95 | 31,524 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Acquisiton | 2020-02-06 | 69,556 | $0.00 | 69,556 | $28.05 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 69,556 | 2030-02-05 | No | 4 | A | Direct |
Footnotes
- The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on February 6, 2021 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through February 6, 2024.
- The sales reported in this Form 4 were effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on May 11, 2019, and represent the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on February 6, 2020. The sales do not represent a discretionary trade by the Reporting Person.
- This transaction was executed in multiple trades at prices ranging from $26.42 to $26.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This option was granted on February 6, 2020 and is scheduled to vest over four years in equal monthly installments beginning on March 6, 2020 through February 6, 2024.
Billionaire Hedge Funds
